Decoding Your Pathology Report
At a Glance
A DCIS pathology report shows how far the abnormal cells extend, whether the surgical margins are clear, the nuclear grade, necrosis, microinvasion, and ER status. These findings help your care team estimate recurrence risk and choose treatment.
Reading a pathology report can feel like learning a foreign language. However, these documents are the “blueprint” for your care. When you look at your report for Ductal Carcinoma In Situ (DCIS), you are looking for specific details that help your doctors determine how aggressive the cells are and how much treatment you need to prevent them from coming back [1][2]. Note that a core needle biopsy report will naturally have less information (such as final margin status) than a final excision (surgical) report.
The Margin Consensus: The 2-mm Target
One of the most important numbers in your final surgical report is the margin. This is the distance between the DCIS cells and the edge of the tissue the surgeon removed.
- Positive Margin: DCIS cells are touching the surgical ink (the “edge”). This increases the risk of the disease returning in the same breast compared to a negative margin [3][4].
- Negative Margin: This generally means no DCIS on ink.
For patients planning to have a lumpectomy followed by whole-breast radiation, the medical consensus for an “adequate” margin target is 2 mm [3][5]. While some reports may show a narrower margin (less than 2 mm), this does not automatically mean you need a mastectomy or even another surgery. In many cases, your doctor may decide that radiation is sufficient to manage the risk of any microscopic cells that might remain [6][7]. A 2 mm clearance is not a universal safety zone for every treatment setting, and recommendations differ when radiation is omitted or a mastectomy is performed.
Nuclear Grade and Comedo Necrosis
The nuclear grade tells you how abnormal the cells look under a microscope. It is scored from 1 to 3:
- Grade 1 (Low): The cells look fairly similar to normal breast cells.
- Grade 2 (Intermediate): The cells look more abnormal.
- Grade 3 (High): The cells look very different from normal cells and tend to grow more quickly. High-grade DCIS is more likely to be associated with a return of the disease or “upstaging” to invasive cancer [8][9].
You may also see the term comedo necrosis. This occurs when the cells in the center of a milk duct grow so fast that they run out of nutrients and die, leaving behind a “plug” of dead tissue [10]. The presence of comedo necrosis often goes hand-in-hand with high-grade DCIS and may indicate a slightly higher risk of the cancer recurring [11].
Architectural Subtypes: How the Cells Grow
Pathologists describe the physical patterns the cells form within the ducts. It is common to have more than one pattern in a single sample.
- Solid: The cells completely fill the duct.
- Cribriform: The cells fill the duct but have small, Swiss-cheese-like holes in the middle.
- Papillary or Micropapillary: The cells grow in finger-like projections or small tufts pointing toward the center of the duct. Micropapillary DCIS can sometimes be more extensive than it appears on imaging [12].
Hormone Receptors and the HER2 Question
Your report will include your Estrogen Receptor (ER) status. If your DCIS is ER-positive (meaning it uses estrogen to grow), taking hormone-blocking medications like tamoxifen can significantly reduce the risk of a future breast cancer in either breast [13][14].
You may notice that HER2 testing—common in invasive breast cancer—is usually missing from a pure DCIS report. Current guidelines from ASCO and NCCN do not routinely recommend HER2 testing for DCIS because there is no evidence that HER2-targeted drugs (like Herceptin) provide a benefit for Stage 0 disease [15][14]. In a major clinical trial, adding HER2-targeted therapy did not significantly reduce the risk of the cancer coming back [16].
Your Pathology Checklist
Ensure you discuss these items when reviewing your final surgical report:
- Size/Extent: How large is the area of DCIS in millimeters or centimeters?
- Margin Clearance: What is the distance (in mm) to the closest surgical edge?
- Nuclear Grade: Is it Grade 1, 2, or 3?
- Necrosis: Is comedo necrosis present or absent?
- Microinvasion: Were there tiny areas where cells broke through the basement membrane?
- ER Status: Is the DCIS Estrogen Receptor positive or negative? [1][13]
Common questions in this guide
What does a 2-mm margin mean after DCIS surgery?
How does nuclear grade affect DCIS treatment?
What is comedo necrosis in a DCIS pathology report?
What does ER-positive DCIS mean for treatment?
Why might HER2 testing be missing from my DCIS report?
What does microinvasion mean in DCIS?
One line in your results can change your plan.
A narrower-than-target margin does not automatically mean more surgery, so ask your doctor whether radiation would be considered. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on ductal breast carcinoma in situ.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
A Nomogram Using Imaging Features to Predict Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ.
Choi BH, Kang S, Cho N, Kim SY
Korean journal of radiology 2024; (25(10)):876-886 doi:10.3348/kjr.2024.0268.
PMID: 39344545 - 2
Spectrum of Ductal Carcinoma In Situ (DCIS) Lesions of the Breast: From Morphology to Molecular Characteristics.
Sathvik G, V P, Joseph LD, Challa CB
Cureus 2024; (16(9)):e69929 doi:10.7759/cureus.69929.
PMID: 39439618 - 3
Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ.
Morrow M, Van Zee KJ, Solin LJ, et al.
Annals of surgical oncology 2016; (23(12)):3801-3810 doi:10.1245/s10434-016-5449-z.
PMID: 27527714 - 4
Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.
Schmitz RSJM, van den Belt-Dusebout AW, Clements K, et al.
BMJ (Clinical research ed.) 2023; (383()):e076022 doi:10.1136/bmj-2023-076022.
PMID: 37903527 - 5
The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis.
Marinovich ML, Azizi L, Macaskill P, et al.
Annals of surgical oncology 2016; (23(12)):3811-3821 doi:10.1245/s10434-016-5446-2.
PMID: 27527715 - 6
Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation.
Tadros AB, Smith BD, Shen Y, et al.
Annals of surgery 2019; (269(1)):150-157 doi:10.1097/SLA.0000000000002439.
PMID: 28742682 - 7
Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins.
Suzuki R, Yoshida M, Oguchi M, et al.
Journal of radiation research 2020; (61(3)):440-446 doi:10.1093/jrr/rraa005.
PMID: 32163143 - 8
Artificial Intelligence-Assisted Invasion Risk Scoring in Tru-Cut Biopsies of Ductal Carcinoma in Situ; Predictive Role of Estrogen Receptor and HER2 Expression.
Uzun E, Bulut K
Turk patoloji dergisi 2026; (42(3)):174-182 doi:10.5146/tjpath.2026.14901.
PMID: 42117201 - 9
Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ.
Miligy IM, Gorringe KL, Toss MS, et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018; (31(12)):1807-1815 doi:10.1038/s41379-018-0086-7.
PMID: 29955142 - 10
Prediction of upstaging in DCIS: the dominant role of pathological over imaging risk factors.
Choi S, Park B, Lee EG, et al.
Breast cancer research and treatment 2025; (213(3)):325-334 doi:10.1007/s10549-025-07768-6.
PMID: 40748441 - 11
Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.
Davis JE, Nemesure B, Mehmood S, et al.
Applied immunohistochemistry & molecular morphology : AIMM 2016; (24(1)):20-5 doi:10.1097/PAI.0000000000000223.
PMID: 26317313 - 12
Breast ductal carcinoma in situ with micro-invasion versus ductal carcinoma in situ: a comparative analysis of clinicopathological and mammographic findings.
Zhang M, Lin Q, Su XH, et al.
Clinical radiology 2021; (76(10)):787.e1-787.e7 doi:10.1016/j.crad.2021.04.011.
PMID: 34052010 - 13
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.
Allison KH, Hammond MEH, Dowsett M, et al.
Archives of pathology & laboratory medicine 2020; (144(5)):545-563 doi:10.5858/arpa.2019-0904-SA.
PMID: 31928354 - 14
Systemic Treatment of Ductal Carcinoma In Situ of the Breast.
Crimini E, Corti C, Repetto M, et al.
Chirurgia (Bucharest, Romania : 1990) 2021; (116(5 Suppl)):S97-S104.
PMID: 34967317 - 15
The clinical significance of HER2 expression in DCIS.
Akrida I, Mulita F
Medical oncology (Northwood, London, England) 2022; (40(1)):16 doi:10.1007/s12032-022-01876-9.
PMID: 36352293 - 16
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
Cobleigh MA, Anderson SJ, Siziopikou KP, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(21)):2367-2374 doi:10.1200/JCO.20.02824.
PMID: 33739848
This page explains DCIS pathology terms for educational purposes and does not replace medical advice. Your breast surgeon and pathology team should interpret your report and discuss the treatment options appropriate for you.